| Ytd | -16.33% | |
| 1y | -23.35% |
| Open | 1.30 | Prev Close | 1.33 | Low | 1.28 | High | 1.32 | Mkt Cap | 80.87M |
| Vol | 144.04K | Avg Vol | 741.65K | EPS | -0.67 | P/E | -1.99 | Forward P/E | -1.25 |
| Beta | 0.22 | Short Ratio | 10.99 | Inst. Own | 7.51% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-08 | 50-d Avg | 1.36 | 200-d Avg | 1.48 | 1yr Est | 12.63 |
MAIA News
90.5% interim disease control rate (DCR) observed with combination therapyInitial Part C efficacy ob
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage bioph
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage bioph
Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Ap
Approximately 72,700 shares of MAIA common stock were purchased by Dr. Vitoc on June 6, 2026, at an
THIO-104 evaluates the efficacy of MAIA's telomere targeting agent, ateganosine, administered in
MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.14) per share which beat the analyst
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage bioph
Potential breakthrough therapeutic targets $50B+ global immunotherapy market1CHICAGO, March 31, 2026
MAIA Biotechnology (AMEX:MAIA) reported quarterly losses of $(0.08) per share which beat the analyst
US stocks down amid Iran-US conflict. Tehran closed Strait of Hormuz & warned of firing on vesse
U.S. stocks traded lower this morning, with the Dow Jones index falling more than 900 points on Tues
Shares of Ouster Inc (NASDAQ:OUST) rose sharply in pre-market trading after the company reported bet
MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biop
Ongoing Phase 3 full approval clinical trial of ateganosine holds high probability of technical succ
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage bioph
MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biop
Key milestone achieved as Company advances clinical program to full approval trial of ateganosine se
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage bioph